



Adding Smiles To Life

Date: February 14, 2025

To
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400051, Maharashtra.

SYMBOL: QMSMEDI

Sub: Outcome of Board meeting

Re: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Ma'am,

With reference to the captioned subject, we wish to inform that the Board of Directors of the Company in its meeting held today, i.e. on February 14, 2025, have inter-alia considered and approved the following:

Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024:

Copy of Unaudited Financial Results (Standalone and Consolidated) for the quarter and Nine months ended December 31, 2024 of the financial year 2024-25 is enclosed herewith.

The aforesaid results were reviewed by the Audit Committee and subsequently, approved and taken on record by the Board of Directors of the Company. We would further like to inform that the Statutory Auditors of the Company have subjected the aforesaid results to "Limited Review" and the same is enclosed herewith.

QMS Medical Allied Services Ltd.

📍 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 🌐 www.qmsmas.com

CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com



Adding Smiles To Life

The meeting commenced at 3.30 PM and concluded at 5.45 P.M.

This is for your information and records.

Thanking you,

Yours sincerely,

FOR QMS MEDICAL ALLIED SERVICES LIMITED

TORAL BHADRA
COMPANY SECRETARY AND COMPLIANCE OFFICER
MEMBERSHIP NO.: A56927
DATE: FEBRUARY 14, 2025
PLACE: MUMBAI

QMS Medical Allied Services Ltd.

📍 1A-1B / 2A-2B, Navkala Bharati Building, Plot No. 16, Prabhat Colony, Road No. 3, Santacruz (East), Mumbai - 400 055.

☎ +91-022 - 6288 1111 🌐 www.qmsmas.com

CIN: L33309MH2017PLC299748; Email ID: mm@qmsmas.com

Independent Auditor's report on quarterly unaudited standalone financial results of QMS Medical Allied Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
QMS Medical Allied Services Limited

Introduction

1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of QMS Medical Allied Services Limited ("the Company") for the quarter ended on December 31, 2024, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Management's Responsibility

2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard ("AS") 25 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's Responsibility

3. Our responsibility is to issue a report on the statement based on our review.

Scope of Review

4. We conducted our review of the statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical and other review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Conclusion

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable



AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

6. The standalone financial results pertaining to quarter ended December 31, 2023 in the Statement were reviewed by the previous auditors and the financial statements for the year ended March 31, 2024 were audited by the predecessor auditors, who had expressed an unmodified opinion/ conclusion on that financial information.
7. The figures for the quarter ended December 31, 2024 are the balancing figures between the unaudited figures for nine months period ended December 31, 2024 and unaudited figures for the half year ended September 30, 2024 which were subject to limited review by the previous auditor.

For H H Dedhia & Associates
Chartered Accountants
(FRN – 148213W)



Harsh H. Dedhia
Proprietor
M No. – 141494
UDIN – 25141494BMLCAR2276



Place: Mumbai
Date: February 14, 2025

QMS MEDICAL ALLIED SERVICES LIMITED

CIN:L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz East Mumbai 400055, Maharashtra, India

Email: mm@qmsmas.com

Web: <https://qmsmas.com/>

Statement of Unaudited Standalone Financial Results for the quarter and nine months ended 31st December 2024. (Rs. In Lacs)

Sl	Particulars	Quarter Ended			Nine Months Ended		Year ended 31.03.2024
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue From Operations						
(a)	Revenue From Operations (Net of taxes)	3,938.45	3,274.04	3,523.51	10,249.23	8,983.80	12,212.80
(b)	Other Income	12.34	9.35	14.53	32.55	34.16	45.56
	Total Income (net)	3,950.79	3,283.39	3,538.04	10,281.78	9,017.97	12,258.36
2	Expenses						
(a)	Cost of Material Consumed	-	-	-	-	-	-
(b)	Purchase of Stock-in-Trade	2,351.13	1,843.76	2,337.13	6,106.90	5,992.42	8,757.74
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	(33.61)	76.99	72.96	(146.78)	(120.33)	(765.31)
(d)	Employee Benefits Expenses	220.23	175.15	159.82	557.29	382.75	550.18
(e)	Finance Cost	131.32	106.86	80.76	322.33	213.60	312.56
(f)	Depreciation and Amortisation Expenses	90.77	82.77	88.36	250.28	255.61	344.00
(g)	Other Expenses	867.01	645.94	469.18	2,181.75	1,289.18	1,835.60
	Total Expenses	3,626.84	2,931.46	3,208.21	9,271.77	8,013.22	11,034.78
3	Profit before exceptional and extraordinary items and tax	323.95	351.93	329.83	1,010.02	1,004.75	1,223.59
4	Exceptional items	-	-	-	-	-	-
5	Profit before extraordinary items and tax	323.95	351.93	329.83	1,010.02	1,004.75	1,223.59
6	Extraordinary items	-	-	-	-	-	-
7	Profit before tax	323.95	351.93	329.83	1,010.02	1,004.75	1,223.59
8	Tax expense						
(a)	Current Tax	90.00	92.00	88.00	274.00	263.00	331.50
(b)	Deferred Tax	(1.89)	(1.25)	(1.94)	(0.56)	(4.08)	(7.65)
(c)	(Excess)/Short Provision for earlier years	1.12	-	(0.51)	1.17	(0.51)	(0.51)
	Total Tax Expense	89.23	90.75	85.55	274.60	258.41	323.34
9	Profit for the period from continuing operations	234.72	261.17	244.28	735.42	746.34	900.24
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Profit/(Loss) for the period	234.72	261.17	244.28	735.42	746.34	900.24
12	Details of Equity Share Capital						
	Paid up equity share capital (Face value of Rs. 10/- each)	1,785.00	1,785.00	1,785.00	1,785.00	1,785.00	1,785.00
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	6,066.38
13	Earnings Per Equity Share (before extraordinary items) (of Rs. 10/-each) (not annualised) (before and after extraordinary items)						
(a)	Basic	1.31	1.46	1.37	4.12	4.18	5.04
(b)	Diluted	1.31	1.46	1.37	4.12	4.18	5.04
	See accompanying note to Financial Results						

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606


Date: 14.02.2025
Place: Mumbai



Notes to Standalone Financial Statements

1. The above unaudited financial results of the company were reviewed by the Audit Committee & approved by the Board of Directors at its meeting held on 14th February 2025. The auditors have expressed an unmodified opinion on the said financial results.
2. The results of the Company are available for investors at www.qmsmas.com and www.nseindia.com.
3. The standalone financial results for the quarter ended on 31st December, 2024 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued unmodified report on unaudited financial results.
4. The Company is operating as a single segment company, engaged in "Healthcare Equipments/Supplies and Services" and hence there is no separate reportable business segment.
5. As per MCA notification dated 16 February, 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of capital & Disclosure Requirements) Regulations, 2009 are exempted from compulsory requirement of adoption of IND-AS, as the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. There are no Investor complaints pending as on 31st December, 2024.
7. The figures for the quarter ended 31st December 2024 are balancing figures between the figures of the nine months ended 31st December 2024 which were subject to limited review and figures for the half year ended 30th September 2024.
8. The figures for the quarter ended 31st December 2023 are balancing figures between the figures of the nine months ended 31st December 2023 which were subject to limited review and figures for the half year ended 30th September 2023 which were subjected to limited review by statutory auditor.
9. Previous year figures have been regrouped/reclassified where required to make them comparable with figures of current period.

**For & on behalf of the Board of Directors of
QMS Medical Allied Services Limited**



Mahesh Makhija
Managing Director
[DIN: 02700606]



Place: Mumbai

Date: 14th February, 2025

Limited Review Report on quarterly unaudited consolidated financial results of QMS Medical Allied Services Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
QMS Medical Allied Services Limited

Introduction

1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") of QMS Medical Allied Services Limited (hereinafter referred to as "the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended on December 31, 2024, attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

Management's Responsibility

2. This statement, which is the responsibility of the Parent's Management and approved by the Board of Directors of the Parent, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard ("AS") 25 "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

Auditor's Responsibility

3. Our responsibility is to express a conclusion on the statement based on our review.

Scope of Review

4. We conducted our review of the statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical and other review procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Statement includes the results of the following entities

Sr. No.	Name of Entity	Relationship
1	Saarthi Healthcare Private Limited	Subsidiary



Conclusion

5. Based on our review conducted and procedures performed as stated in paragraph 4 above and based on the management certified financial statements referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable AS and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.


Other Matter

6. The Financial Results pertaining to quarter ended December 31, 2023 in the Statement were reviewed by the previous auditors and the financial statements for the year ended March 31, 2024 were audited by the predecessor auditors, who had expressed an unmodified opinion/conclusion on that financial information.
7. We did not review the interim financial information/ financial results of subsidiary included in the statement, whose interim financial information/ financial results reflects total income of Rs. 928.43 lakhs, total net profit after tax of Rs. 273.71 lakhs for the nine months period ended December 31, 2024, as considered in the statement. These interim financial information/ financial results have been certified by management which have been furnished to us by the Parent's management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary is based solely on the reports of the other auditor and procedures performed by us stated in paragraph 4 above. Our conclusion is not modified in respect of this matter.
8. The figures for the quarter ended December 31, 2024 are the balancing figures between the unaudited figures for nine months period ended December 31, 2024 and unaudited figures for the half year ended September 30, 2024 which were subject to limited review by the previous auditor.

For H H Dedhia & Associates

Chartered Accountants

(FRN – 148213W)



Harsh H. Dedhia

Proprietor

M No. – 141494

UDIN – 25141494BMLCAS8172



Place: Mumbai

Date: February 14, 2025

QMS MEDICAL ALLIED SERVICES LIMITED

CIN:L33309MH2017PLC299748

Registered Office: A1 A2/B1 B2, Navkala Bharti Bldg Plot No16 Prabhat Colony opp near Santacruz Bus depot Santacruz East Mumbai 400055, Maharashtra, India

Email: mm@qmsmas.com

Web: <https://qmsmas.com/>

Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended 31st December 2024. (Rs. In Lakhs)

Sn	Particulars	Quarter Ended			Nine Months Ended		Year ended 31.03.2024
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue From Operations						
(a)	Revenue From Operations (Net of taxes)	4,386.55	3,719.88	3,523.51	11,143.18	8,983.80	12,212.80
(b)	Other Income	19.12	32.78	14.53	62.75	34.16	45.56
	Total Income (net)	4,405.67	3,752.66	3,538.04	11,205.93	9,017.97	12,258.36
2	Expenses						
(a)	Cost of Material Consumed	-	-	-	-	-	-
(b)	Purchase of Stock-in-Trade	2,357.16	1,844.36	2,337.13	6,113.53	5,992.42	8,757.74
(c)	Changes in Inventories of Finished Goods, Work in Progress and Stock in Trade	-33.61	76.99	72.96	(146.78)	(120.33)	(765.31)
(d)	Employee Benefits Expenses	285.43	258.00	159.82	705.35	382.75	550.18
(e)	Finance Cost	131.40	106.93	80.76	322.48	213.60	312.56
(f)	Depreciation and Amortisation Expenses	86.23	83.62	88.36	246.60	255.61	344.00
(g)	Other Expenses	1,082.79	816.45	469.18	2,568.04	1,289.18	1,835.60
	Total Expenses	3,909.41	3,186.35	3,208.21	9,809.22	8,013.22	11,034.78
3	Profit before exceptional and extraordinary items and tax	496.26	566.32	329.83	1,396.72	1,004.75	1,223.59
4	Exceptional items	-	-	-	-	-	-
5	Profit before extraordinary items and tax	496.26	566.32	329.83	1,396.72	1,004.75	1,223.59
6	Extraordinary items	-	-	-	-	-	-
7	Profit before tax	496.26	566.32	329.83	1,396.72	1,004.75	1,223.59
8	Tax expense						
(a)	Current Tax	150.08	144.62	88.00	386.69	263.00	331.50
(b)	Deferred Tax	-1.20	(1.63)	(1.94)	(0.27)	(4.08)	(7.65)
(c)	(Excess)/Short Provision for earlier years	1.12	-	(0.51)	1.17	(0.51)	(0.51)
	Total Tax Expense	149.99	142.98	85.55	387.59	258.41	323.34
9	Profit for the period from continuing operations	346.27	423.33	244.28	1,009.12	746.34	900.24
10	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
11	Profit/(Loss) for the period	346.27	423.33	244.28	1,009.12	746.34	900.24
	Profit for the period attributable to:						
	Owners of the company	291.61	343.87	244.28	875.01	746.34	900.24
	Non-controlling Interest	54.66	79.46	-	134.12	-	-
12	Details of Equity Share Capital						
	Paid up equity share capital (Face value of Rs.10/- each)	1,785.00	1,785.00	1,785.00	1,785.00	1,785.00	1,785.00
	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	6,066.38
13	Earnings Per Equity Share (before extraordinary items) (of Rs. 10/-each) (not annualised) (before and after extraordinary items)						
(a)	Basic	1.63	1.93	1.37	4.90	4.18	5.04
(b)	Diluted	1.63	1.93	1.37	4.90	4.18	5.04
	See accompanying note to Financial Results						

FOR QMS MEDICAL ALLIED SERVICES LIMITED

Mr. MAHESH PAHALRAJ MAKHIJA
Managing Director
DIN: 02700606


Date: 14.02.2025
Place: Mumbai



Notes:

1. The above unaudited consolidated financial results of the company were reviewed and recommended by the audit committee on 14th February, 2025 and subsequently approved by the Board of Directors at its meeting held on 14th February, 2025. The review report has been filed with stock exchange and is available on the Company's website.
2. The figures for the quarter ended 31st December, 2024 are balancing figures between the unaudited year to date figures and the published figures of the second quarter of the financial year which are subjected to limited review.
3. The consolidated financial results for the quarter ended 31st December, 2024 have been subjected to Limited Review by statutory auditors of the company and the statutory auditors have issued an unmodified report on unaudited financial results.
4. The above consolidated financial results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India ('SEBI'), and the Accounting Standards (AS) prescribed under Section 133 of the Companies Act, 2013.
5. The Parent Company's and its subsidiary company's only identifiable reportable segment is "Healthcare Equipments/Supplies & Services" and hence disclosure of Segment wise information is not applicable under Accounting Standard – 17 "Segment Reporting".
6. Previous periods / year figures are regrouped and rearranged wherever necessary including on account of amendment in Division II to Schedule III of Companies Act 2013 to conform current period presentation.
7. The results of the Company are available for investors at www.qmsmas.com and www.nseindia.com.

**For & On behalf of the Board of Directors
of QMS Medical Allied Services Limited.**


Mahesh Makhija
Managing Director
[DIN: 02700606]



Place: Mumbai
Date: 14th February, 2025